NCT04338724View on ClinicalTrials.gov

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 27, 2019

Primary Completion Date

September 21, 2020

Study Completion Date

September 21, 2020

Conditions
Advanced Solid Tumor
Interventions
DRUG

CS1002

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Trial Locations (1)

Unknown

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY